文档介绍:肿瘤综合治疗电子杂志 2021 年第 7 卷第 3 期 ● 病例报道 ● 55
DOI :.03-11
1例基于瑞戈非尼的抗血管生成治疗KRAS突变右
半结肠癌的体会
梁紫葳,姚健楠,安广宇,葛洋(首都医科大学附属北京朝阳医院 肿瘤科,北京 100020)
【摘要】 结肠癌是一种常见的消化系统恶性肿瘤,鼠肉瘤病毒致癌基因(kirsten rat sarcoma viral oncogene,KRAS)突变率高,
预后较差,本文报道2017年9月首都医科大学附属北京朝阳医院肿瘤科收治的1例经FOLFIRI方案(亚叶酸钙+ 5-氟尿嘧啶+
依立替康)、卡培他滨、贝伐珠单抗+雷替曲塞等多线治疗疾病进展后,接受基于瑞戈非尼的多线治疗后依旧生存的KRAS突
变右半结肠癌病例。目前患者总生存时间为46个月,提示患者可以从持续抗血管生成治疗中获益,为临床治疗KRAS突变右
半结肠癌提供新思路。
【关键词】 结肠癌 ;KRAS突变 ;瑞戈非尼
Treatment experience of anti-angiogenic therapy based on regorafenib for right-side colon cancer with KRAS mutation
Liang Ziwei, Yao Jiannan, An Guangyu, Ge Yang (Department of Oncology, Beijing Chao-Yang Hospital, Capital Medical University,
Beijing 100020, China)
Corresponding author: Ge Yang, E-mail: interna-******@
【Abstract】 Colon cancer is a most common digestive system tumor, with high kirsten rat sarcoma viral oncogene (KRAS) mutation
rate and poor prognosis. This article reports a case of right-side colon cancer with KRAS mutation, which was admitted and treated in the
Department of Oncology, Beijing Chao-Yang Hospital in September 2017. The disease progressed after multiline therapy of FOLFIRI
regimen (calcium folinate + 5-fluorouracil + irinotecan), ca